Rakhshita Dhar

Dallas-Founded Biopharma Firm Raises $120M to Expand its Pipeline

by | Jun 29, 2022
ReCode Therapeutics, a biopharmaceutical startup using a non-viral lipid nanoparticle delivery platform for gene therapies, has closed a $120 million extension to a funding round it raised last year to help bring its lead programs to human trials and “follow the science” to target new diseases. With a research team working out of BioLabs' life sciences facility at Pegasus Park, ReCode aims to grow its global team from about 70 to 100 over the next year.
MORE